This physician survey is part of an overall evaluation of the Centers for Medicare and Medicaid Services (CMS)'s congressionally mandated Competitive Acquisition for Part B Drugs Program (CAP). MMA section 303(d) requires the implementation of the CAP for those drugs and biologicals covered by Medicare Part B that are not paid on a cost or prospective payment system. Since summer 2006 (the original date of January 1, 2006 was delayed), physicians have been given a choice between (1) buying and billing for these covered drugs under the average sales price (ASP) system mandated in section 303(c) of the MMA; or (2) obtaining these drugs from vendors selected for the CAP in a competitive bidding process. If the physician elects to obtain drugs from a CAP vendor, the vendor will bill Medicare for the drug (the physician will continue to bill Medicare for any drug administration fees). The CAP is therefore a major change in the way Part B-covered drugs and biologicals are acquired and reimbursed for, requiring CMS to consider many design options. The CAP mandate includes a Report to Congress, which will include results from this physician survey.
PL:
Pub.L. 108 - 173 1
Name of Law: Medicare Prescription Drug, Improvement, and Modernization Act of 2003
A one-time increase in provider burden of 296.5 hours is necessary to field a survey of physicians to assess physician satisfaction with the Competitive Acquisition Program for Pat B Drugs and Biologicals. Section 303(d)(2) of the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003 (Pub. L. 108-173) requires the Secretary of the Department of Health and Human Services to submit a Report to Congress by July 1, 2008 that includes information on physician satisfaction with this program. A survey is the only feasible method of systematically collecting this information. The survey is limited to only questions that address satisfaction, including reasons for participating, as well as information about participating and non-participating physicians that may permit comparisons between those who elected to participate and those who did not. The burden to individual physicians is small for physicians participating in the program (15 minutes in total) and minimal for those not participating (eight minutes in total). There are no capital, startup, operation, or maintenance costs to respondents.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
CMS-10223 CAP_OMB_package_revised(3) 12_12_07.doc
Medicare Competitive Acquisition Program (CAP) for Part B Drugs Evaluation: CAP Physician Survey (CMS-10223)